To access this material please log in or register

Register Authorize

Effect of trimetazidine on left ventricular remodeling and function in patients with chronic heart failure: scientific and practical aspects

Giliarevskiy S. R., Orlov V. A., Kuzmina I. M.

Keywords: treatment, myocardial remodeling, trimetazidine, CHF

DOI: 10.18087/rhfj.2012.6.1750

The review provides data of the randomized clinical studies, evidencing that administration of trimetazidine leads to improvement of cardiac function in CHF patients of both ischemic and non-ischemic nature, and also to lower severity of cardiac remodeling.
  1. Kannel W. B. Incidence and epidemiology of heart failure. Heart Fail Rev. 2000;5 (2):167–173.
  2. Sliwa K, Damasceno A, Mayosi BM. Epidemiology and etiology of cardiomyopathy in Africa. Circulation. 2005;112 (23):3577–3583.
  3. Najafi F, Jamrozik K, Dobson AJ. Understanding the ‘epidemic of heart failure’: a systematic review of trends in determinants of heart failure. Eur J Heart Fail. 2009;11 (5):472–479.
  4. Stewart S, MacIntyre K, Hole DJ et al. More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail. 2001;3 (3):315–322.
  5. Hunt SA, Abraham WT, Chin MH et al. 2009 focused update incorporated into the ACC / AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation / American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009 Apr 14;119 (14):e391–479.
  6. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling – concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol. 2000;35 (3):569–582.
  7. Sutton M, Pfeffer M, Plappert T et al. Quantitative two-dimensi­onal echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation. 1994;89 (1):68–75.
  8. Solomon SD, Skali H, Anavekar NS et al. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. Circulation. 2005;111 (25):3411–3419.
  9. St John Sutton M, Ghio S, Plappert T et al. Cardiac resynchronization induces major structural and functional reverse remodeling in patients with New York Heart Association class I / II heart failure. Circulation. 2009;120 (19):1858–1865.
  10. Kramer DG, Trikalinos TA, Kent DM et al. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. J Am Coll Cardiol. 2010;56 (5):392–406.
  11. Palaniswamy C, Mellana WM, Selvaraj DR, Mohan D. Metabolic modulation: a new therapeutic target in treatment of heart failure. Am J Ther. 2011;18 (6):e197–201.
  12. Di Napoli P., Barsotti A. Prognostic relevance of metabolic approach in patients with heart failure. Curr Pharm Des. 2009;15 (8):883–892.
  13. Fragasso G, Spoladore R, Cuko A, Palloshi A. Modulation of fatty acids oxidation in heart failure by selective pharmacological inhibition of 3‑ketoacyl coenzyme-A thiolase. Curr Clin Pharmacol. 2007;2 (3):190–196.
  14. Fantini E, Demaison L, Sentex E et al. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Mol Cell Cardiol. 1994;26 (8):949–958.
  15. Bertomeu-Gonzalez V, Bouzas-Mosquera A, Kaski JC. Role of trimetazidine in management of ischemic cardiomyopathy. Am J Cardiol. 2006;98 (5A): 19J-24J.
  16. Onay-Besikci A, Ozkan SA. Trimetazidine revisited: a comprehensive review of the pharmacological effects and analytical techniques for the determination of trimetazidine. Cardiovasc Ther. 2008;26 (2):147–165.
  17. Khan M, Meduru S, Mostafa M et al. Trimetazidine, administered at the onset of reperfusion, ameliorates myocardial dysfunction and injury by activation of p38 mitogen-activated protein kinase and Akt signaling. J Pharmacol Exp Ther. 2010;333 (2):421–429.
  18. Yin RX, Liang WW, Liu TW et al. Inhibitory effect of trimetazidine on cardiac myocyte apoptosis in rabbit model of ischemiae-reperfusion. Chin Med Sci J. 2004;19 (4):242.
  19. Wisel S, Khan M, Kuppusamy ML et al. Pharmacological preconditioning of mesenchymal stem cells with trimetazidine (1- [2,3,4‑trimethoxybenzyl] piperazine) protects hypoxic cells against oxidative stress and enhances recovery of myocardial function in infarcted heart through Bcl-2 expression. J Pharmacol Exp Ther. 2009;329 (2):543–550.
  20. Park KH, Park WJ, Kim MK et al. Effects of trimetazidine on endothelial dysfunction after sheath injury of radial artery. Am J Cardiol. 2010;105 (12):1723–1727.
  21. Liu X, Gai Y, Liu F et al. Trimetazidine inhibits pressure overload-induced cardiac fibrosis through NADPH oxidase-ROS-CTGF pathway. Cardiovasc Res. 2010;88 (1):150–158.
  22. Belardinelli R, Purcaro A. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy. Eur Heart J. 2001;22 (23):2164–2170.
  23. Di Napoli P, Taccardi AA, Barsotti A. Long-term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart. 2005;91 (2):161–165.
  24. Di Napoli P, Di Giovanni P, Gaeta MA et al. Trimetazidine and reduction in mortality and hospitalization in patients with ische­mic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d'Abruzzo Trimetazidine Trial. J Cardiovasc Pharmacol. 2007;50 (5):585–589.
  25. El-Kady T, El-Sabban K, Gabaly M et al. Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24‑month study. Am J Cardiovasc Drugs. 2005;5 (4):271–278.
  26. Tuunanen H, Engblom E, Naum A et al. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dila­ted cardiomyopathy. Circulation. 2008;118 (12):1250–1258.
  27. Lloyd-Jones D, Adams R, Carnethon M et al. Heart disease and stroke statistics – 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommitte. Circulation. 2009;119 (3):e21–181.
  28. Packer M, Carver JR, Rodeheffer RJ et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991;325 (21):1468–1475.
  29. Cuffe MS, Califf RM, Adams KF Jr et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a rando­mized controlled trial. JAMA. 2002;287 (12):1541–1547.
  30. Bohm M, Swedberg K, Komajda M et al. on behalf of the SHIFT investigators. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomized placebo-controlled trial. Lancet. 2010;376 (9744):886–894.
  31. Tardif JC, O'Meara E, Komajda M et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT – echocardiography substudy. Eur Heart J. 2011;32 (20):2507–2515.
  32. Gao D, Ning N, Niu X et al. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart. 2011;97 (4):278–286.
  33. Gunes Y, Guntekin U, Tuncer M, Sahin M. Improved left and right ventricular functions with trimetazidine in patients with heart failure: a tissue Doppler study. Heart Vessels. 2009;24 (4):277–282.
  34. Marazzi G, Gebara O, Vitale C et al. Effect of trimetazidine on quali­ty of life in elderly patients with ischemic dilated cardiomyopathy. Adv Ther. 2009;26 (4):455–461.
  35. Belardinelli R, Lacalaprice F, Faccenda E, Volpe L. Trimetazidine potentiates the effects of exercise training in patients with ische­mic cardiomyopathy referred for cardiac rehabilitation. Eur J Cardiovasc Prev Rehabil. 2008;15 (5):533–540.
  36. Belardinelli R, Cianci G, Gigli M et al. Effects of trimetazidine on myocardial perfusion and left ventricular systolic function in type 2 diabetic patients with ischemic cardiomyopathy. J Cardiovasc Pharmacol. 2008;51 (6):611–615.
  37. Di Napoli P, Di Giovanni P, Gaeta MA et al. Beneficial effects of trimetazidine treatment on exercise tolerance and B-type natriuretic peptide and troponin T plasma levels in patients with stable ischemic cardiomyopathy. Am Heart J. 2007;154 (3):602.e1–5.
  38. Fragasso G, Palloshi A, Puccetti P et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol. 2006;48 (5):992–998.
  39. Fragasso G, Perseghin G, De Cobelli F et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine / adenosine triphosphate ratio in patients with heart failure. Eur Heart J. 2006;27 (8):942–948.
  40. Vitale C, Wajngaten M, Sposato B et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J. 2004;25 (20):1814–1821.
  41. Thrainsdottir IS, von Bibra H, Malmberg K, Rydén L. Effects of trimetazidine on left ventricular function in patients with type 2 diabetes and heart failure. J Cardiovasc Pharmacol. 2004;44 (1):101–108.
  42. Rosano GM, Vitale C, Sposato B et al. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study. Cardiovasc Diabetol. 2003;2:16.
  43. Fragasso G, Piatti Md PM, Monti L et al. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J. 2003;146 (5):E18.
  44. Brottier L, Barat JL, Combe C et al. Therapeutic value of a cardioprotective agent in patients with severe ischaemic cardiomyopathy. Eur Heart J. 1990;11 (3):207–212.
  45. Sisakian H, Torgomyan A, Barkhudaryan A. The effect of trimetazidine on left ventricular systolic function and physical tolerance in patients with ischaemic cardiomyopathy. Acta Cardiol. 2007;62 (5):493–499.
  46. Zhang L, Lu Y, Jiang H et al. Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis. J Am Coll Cardiol. 2012;59 (10):913–922.
  47. Cera M, Salerno A, Fragasso G et al. Beneficial electrophysiological effects of trimetazidine in patients with postischemic chronic heart failure. J Cardiovasc Pharmacol Ther. 2010;15 (1):24–30.
  48. Zemljic G, Bunc M, Vrtovec B. Trimetazidine shortens QTc interval in patients with ischemic heart failure. J Cardiovasc Pharmacol Ther. 2010;15 (1):31–36.
  49. Belardinelli R, Solenghi M, Volpe L, Purcaro A. Trimetazidine improves endothelial dysfunction in chronic heart failure: an antioxidant effect. Eur Heart J. 2007;28 (9):1102–1108.
Giliarevskiy S. R., Orlov V. A., Kuzmina I. M. Effect of trimetazidine on left ventricular remodeling and function in patients with chronic heart failure: scientific and practical aspects. Russian Heart Failure Journal. 2012;13(6):365-371

To access this material please log in or register

Register Authorize
Ru En